Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.
The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.
Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.
The company's shares slipped past 1% in recent Monday trade.
Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.